Review

mouse monoclonal dkk3 antibody (Bio X Cell)

Bio X Cell is a verified supplier

Bio X Cell manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio X Cell mouse monoclonal dkk3 antibody

Fig. 1 High <t>DKK3</t> expression is associated with worse patient survival across different cancer types. (A) DKK3 expression in normal adjacent tissues and tumors of patients from TCGA-PAAD, HNSC, THYM and DLBC. (B) The overall survival analysis of patients with high or low DKK3 expression from TCGA (pan-cancer), STAD, BLCA, GMB, HNSC and MESO. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated by log-rank test or unpaired Student’s t-test

Mouse Monoclonal Dkk3 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal dkk3 antibody/product/Bio X Cell
Average 93 stars, based on 3 article reviews

mouse monoclonal dkk3 antibody - by Bioz Stars, 2026-06

93/100 stars

Images

1) Product Images from "Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy."

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

Journal: BMC cancer

doi: 10.1186/s12885-025-14075-2

Fig. 1 High DKK3 expression is associated with worse patient survival across different cancer types. (A) DKK3 expression in normal adjacent tissues and tumors of patients from TCGA-PAAD, HNSC, THYM and DLBC. (B) The overall survival analysis of patients with high or low DKK3 expression from TCGA (pan-cancer), STAD, BLCA, GMB, HNSC and MESO. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated by log-rank test or unpaired Student’s t-test

Figure Legend Snippet: Fig. 1 High DKK3 expression is associated with worse patient survival across different cancer types. (A) DKK3 expression in normal adjacent tissues and tumors of patients from TCGA-PAAD, HNSC, THYM and DLBC. (B) The overall survival analysis of patients with high or low DKK3 expression from TCGA (pan-cancer), STAD, BLCA, GMB, HNSC and MESO. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated by log-rank test or unpaired Student’s t-test

Techniques Used: Expressing

Fig. 2 DKK3 expression is associated with immunosuppressive TME across different cancer types. (A) The interrelation of DKK3 expression with the infiltration percentage of CD8+ T cells in tumor samples from TCGA-BRCA, COAD, ESCA, LUSC and PAAD. (B) The interrelation of DKK3 expression with the infiltration percentage of Th1 cells in tumor samples from TCGA-BRCA, COAD, KICH, LGG and STAD. (C) The interrelation of DKK3 expression with the infiltration percentage of Treg cells in tumor samples from TCGA-BLCA, COAD, LUAD, PAAD and PRAD. (D) The interrelation of DKK3 expression with the infiltration percentage of M2 macrophages in tumor samples from TCGA-BLCA, COAD, KICH, READ and TGCT. (E) The interrelation of DKK3 expression with the infiltration percentage of MDSCs in tumors from TCGA-CESC, ESCA, HNSC, MESO and SKCM

Figure Legend Snippet: Fig. 2 DKK3 expression is associated with immunosuppressive TME across different cancer types. (A) The interrelation of DKK3 expression with the infiltration percentage of CD8+ T cells in tumor samples from TCGA-BRCA, COAD, ESCA, LUSC and PAAD. (B) The interrelation of DKK3 expression with the infiltration percentage of Th1 cells in tumor samples from TCGA-BRCA, COAD, KICH, LGG and STAD. (C) The interrelation of DKK3 expression with the infiltration percentage of Treg cells in tumor samples from TCGA-BLCA, COAD, LUAD, PAAD and PRAD. (D) The interrelation of DKK3 expression with the infiltration percentage of M2 macrophages in tumor samples from TCGA-BLCA, COAD, KICH, READ and TGCT. (E) The interrelation of DKK3 expression with the infiltration percentage of MDSCs in tumors from TCGA-CESC, ESCA, HNSC, MESO and SKCM

Techniques Used: Expressing

Fig. 3 DKK3 inhibits CD8+ T cell activation and Th1 differentiation ex vivo. (A) Primary CD4+ or CD8+ T cells isolated and sorted by MACS were treated with IL-2 (20 ng/mL) and IL-15 (20 ng/mL), and co-cultured with DKK3 recombinant protein (50 ng/mL). After 48 h co-culture, the activation level of CD8+ T cells was measured by the expressions of (B) CD25, (C) CD69, (D) CD107a and (E) IFN-γ by flow cytometry. And the expression of (F) T-bet and (G) GATA3 in CD4+ T cells were measured by flow cytometry. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Figure Legend Snippet: Fig. 3 DKK3 inhibits CD8+ T cell activation and Th1 differentiation ex vivo. (A) Primary CD4+ or CD8+ T cells isolated and sorted by MACS were treated with IL-2 (20 ng/mL) and IL-15 (20 ng/mL), and co-cultured with DKK3 recombinant protein (50 ng/mL). After 48 h co-culture, the activation level of CD8+ T cells was measured by the expressions of (B) CD25, (C) CD69, (D) CD107a and (E) IFN-γ by flow cytometry. And the expression of (F) T-bet and (G) GATA3 in CD4+ T cells were measured by flow cytometry. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques Used: Activation Assay, Ex Vivo, Isolation, Cell Culture, Recombinant, Co-Culture Assay, Flow Cytometry, Expressing

Fig. 4 DKK3 blockade controls tumor growth in different mouse cancer models. (A-B) The tumor volume and overall survival of LLC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (C-D) The tumor volume and overall survival of MC38-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (E-F) The tumor volume and overall survival of MFC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (G-H) The tumor volume and overall survival of Pan02-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Figure Legend Snippet: Fig. 4 DKK3 blockade controls tumor growth in different mouse cancer models. (A-B) The tumor volume and overall survival of LLC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (C-D) The tumor volume and overall survival of MC38-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (E-F) The tumor volume and overall survival of MFC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (G-H) The tumor volume and overall survival of Pan02-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques Used:

Fig. 5 DKK3 blockade remodels the tumor immune microenvironment of different cancers. At the treatment endpoint, the percentages of (A) CD8+/ CD3+ cells, (B) IFNγ+/CD8+ T cells, (C) T-bet+/CD8+ cells, (D) CD164+/F4/80+ cells, and (E) Gr-1+/CD11b+ cells in tumors of the syngeneic LLC, MC38, MFC and Pan02 models were detected by flow cytometry (n = 5 per group). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Figure Legend Snippet: Fig. 5 DKK3 blockade remodels the tumor immune microenvironment of different cancers. At the treatment endpoint, the percentages of (A) CD8+/ CD3+ cells, (B) IFNγ+/CD8+ T cells, (C) T-bet+/CD8+ cells, (D) CD164+/F4/80+ cells, and (E) Gr-1+/CD11b+ cells in tumors of the syngeneic LLC, MC38, MFC and Pan02 models were detected by flow cytometry (n = 5 per group). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques Used: Flow Cytometry

Fig. 6 Combined blockade of DKK3 and PD-1 triggers synergistic anti-tumor effects. (A) The tumor volume of LLC-challenged mice with DKK3-4.22 (10 mg/kg) and / or anti-PD-1 treatment (10 mg/kg). (B) The tumor volume in each group of the LLC mouse model. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Figure Legend Snippet: Fig. 6 Combined blockade of DKK3 and PD-1 triggers synergistic anti-tumor effects. (A) The tumor volume of LLC-challenged mice with DKK3-4.22 (10 mg/kg) and / or anti-PD-1 treatment (10 mg/kg). (B) The tumor volume in each group of the LLC mouse model. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques Used:

Image Search Results

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 1 High DKK3 expression is associated with worse patient survival across different cancer types. (A) DKK3 expression in normal adjacent tissues and tumors of patients from TCGA-PAAD, HNSC, THYM and DLBC. (B) The overall survival analysis of patients with high or low DKK3 expression from TCGA (pan-cancer), STAD, BLCA, GMB, HNSC and MESO. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated by log-rank test or unpaired Student’s t-test

Article Snippet: They received intraperitoneal injections of 10 mg/kg of a mouse monoclonal DKK3 antibody (DKK3-4.22, BE0385, Bio X Cell), a mouse functional PD-1 antibody (BE0146, Bio X Cell), or a combination of both.

Techniques: Expressing

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 2 DKK3 expression is associated with immunosuppressive TME across different cancer types. (A) The interrelation of DKK3 expression with the infiltration percentage of CD8+ T cells in tumor samples from TCGA-BRCA, COAD, ESCA, LUSC and PAAD. (B) The interrelation of DKK3 expression with the infiltration percentage of Th1 cells in tumor samples from TCGA-BRCA, COAD, KICH, LGG and STAD. (C) The interrelation of DKK3 expression with the infiltration percentage of Treg cells in tumor samples from TCGA-BLCA, COAD, LUAD, PAAD and PRAD. (D) The interrelation of DKK3 expression with the infiltration percentage of M2 macrophages in tumor samples from TCGA-BLCA, COAD, KICH, READ and TGCT. (E) The interrelation of DKK3 expression with the infiltration percentage of MDSCs in tumors from TCGA-CESC, ESCA, HNSC, MESO and SKCM

Techniques: Expressing

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 3 DKK3 inhibits CD8+ T cell activation and Th1 differentiation ex vivo. (A) Primary CD4+ or CD8+ T cells isolated and sorted by MACS were treated with IL-2 (20 ng/mL) and IL-15 (20 ng/mL), and co-cultured with DKK3 recombinant protein (50 ng/mL). After 48 h co-culture, the activation level of CD8+ T cells was measured by the expressions of (B) CD25, (C) CD69, (D) CD107a and (E) IFN-γ by flow cytometry. And the expression of (F) T-bet and (G) GATA3 in CD4+ T cells were measured by flow cytometry. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques: Activation Assay, Ex Vivo, Isolation, Cell Culture, Recombinant, Co-Culture Assay, Flow Cytometry, Expressing

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 4 DKK3 blockade controls tumor growth in different mouse cancer models. (A-B) The tumor volume and overall survival of LLC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (C-D) The tumor volume and overall survival of MC38-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (E-F) The tumor volume and overall survival of MFC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (G-H) The tumor volume and overall survival of Pan02-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques:

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 5 DKK3 blockade remodels the tumor immune microenvironment of different cancers. At the treatment endpoint, the percentages of (A) CD8+/ CD3+ cells, (B) IFNγ+/CD8+ T cells, (C) T-bet+/CD8+ cells, (D) CD164+/F4/80+ cells, and (E) Gr-1+/CD11b+ cells in tumors of the syngeneic LLC, MC38, MFC and Pan02 models were detected by flow cytometry (n = 5 per group). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques: Flow Cytometry

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 6 Combined blockade of DKK3 and PD-1 triggers synergistic anti-tumor effects. (A) The tumor volume of LLC-challenged mice with DKK3-4.22 (10 mg/kg) and / or anti-PD-1 treatment (10 mg/kg). (B) The tumor volume in each group of the LLC mouse model. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques:

Review

Structured Review

Images

1) Product Images from "Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy."

Similar Products

Image Search Results